CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/37285333

Research summary

This study evaluates the anti-tumor efficacy of CCX559, an orally administered small molecule inhibitor of PD-L1. CCX559 effectively inhibits PD-L1 interactions, enhances T-cell activation, and demonstrates significant tumor growth inhibition in human PD-L1-expressing murine tumor models.

Key outcome of the study

CCX559 selectively inhibits human PD-L1 binding to PD-1 and CD80, enhances T-cell receptor signaling and activation, induces PD-L1 dimerization and internalization, and demonstrates significant tumor growth inhibition in MC38-hPD-L1 tumor-bearing mice.

Mouse model

MC38-hPD-L1 tumor model developed by genOway, in which the murine MC38 colon carcinoma cell line was engineered to express human PD-L1, enabling the assessment of human-specific PD-L1 inhibitors like CCX559 in an immunocompetent setting.

TARGET:
Cd274
PD-L1, B7-H1

Keywords

Cancer immunotherapy, PD-L1 inhibition, T-cell activation, Tumor growth inhibition

Technical specifications

MC38-hPD-L1 tumor model, Human PD-L1 expression, In vivo efficacy assessment, T-cell activation assays

Related products

Catalogue product

genO-MC38-hPD-L1-LZ

The genO-MC38-hPD-L1-LZ clonal cell line expresses high levels of  human PD-L1 and forms solid tumors in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

Customized product

No items found.